
Figure S1 Genomic features of patients with GC who received RAM-containing therapies.

DNA and RNA were extracted from FFPE tumor samples before treatment and were subjected to the Oncomine™ Comprehensive Assay version 3 to detect gene mutations, copy number variants and fusions across multiple genes. *TP53* were frequently mutated (10/17) and *ERBB2*, *MET*, *FGFR2*, or *KRAS*, amplification, or a *RHOA* mutation were also identified. In contrast, all were MMR proficient GC and only one was EBV-positive GC (an arrow). RTK, receptor tyrosine kinase; NA, not available.